Next Article in Journal
Clinical Predictors of Preeclampsia in Pregnant Women with Chronic Kidney Disease
Previous Article in Journal
Assessment of the Relationship between Selected Factors and Stress-Coping Strategies in Handcyclists—A Preliminary Study
Article

BRCA1 and BRCA2 Gene Mutations and Lung Cancer Risk: A Meta-Analysis

1
Department of Oncology, Tainan Hospital, Ministry of Health and Welfare, Tainan 700, Taiwan
2
Department of Internal Medicine, National Cheng Kung University Hospital, College, Tainan 700, Taiwan
3
Tainan Municipal Hospital, Tainan 700, Taiwan
4
Department of Public Health, College of Medicine, National Cheng Kung University, Tainan 700, Taiwan
5
Department of Public Health, College of Public Health, China Medical University, Taichung 404, Taiwan
6
Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung 413, Taiwan
7
College of Intelligence, National Taichung University of Science and Technology, Taichung 404, Taiwan
*
Author to whom correspondence should be addressed.
Medicina 2020, 56(5), 212; https://doi.org/10.3390/medicina56050212
Received: 23 March 2020 / Revised: 21 April 2020 / Accepted: 21 April 2020 / Published: 27 April 2020
Background and objective: BRCA1 and BRCA2 are associated with many cancer types in addition to hereditary breast and ovarian cancers. However, their relation to lung cancer remains to be explored. Materials and Methods: Observation studies were systematically reviewed to explore the association of BRCA1 or BRCA2 with lung cancer. PubMed, MEDLINE [EBSCOhost], and relevant articles published up to 7 January 2020 were searched. Odd ratio (OR), standardized morbidity rate (SMR), and cancer-specific standardized incidence ratios (SIRs) were pooled together as relative risk (RR) estimates (95% confidence interval [CI], 0.66–1.40). Results: Thirteen studies were included for analysis. Results showed that the RR of BRCA2 is 0.76 (95% CI, 0.48–1.19), the overall RR is 0.96 (95% CI, 0.66–1.40), and that of BRCA1 is 0.66 (95% CI, 0.41–1.05), indicating that it was not associated with lung cancer. Conclusion: With the limitation of the retrospective study design and severe heterogeneity, these results inform clinicians and relevant families that BRCA1 and BRCA2 mutation carriers have no increased risk of lung cancer. View Full-Text
Keywords: lung cancer; BRCA1; BRCA2; meta-analysis lung cancer; BRCA1; BRCA2; meta-analysis
Show Figures

Figure 1

MDPI and ACS Style

Lee, Y.-C.; Lee, Y.-C.; Li, C.-Y.; Lee, Y.-L.; Chen, B.-L. BRCA1 and BRCA2 Gene Mutations and Lung Cancer Risk: A Meta-Analysis. Medicina 2020, 56, 212. https://doi.org/10.3390/medicina56050212

AMA Style

Lee Y-C, Lee Y-C, Li C-Y, Lee Y-L, Chen B-L. BRCA1 and BRCA2 Gene Mutations and Lung Cancer Risk: A Meta-Analysis. Medicina. 2020; 56(5):212. https://doi.org/10.3390/medicina56050212

Chicago/Turabian Style

Lee, Yen-Chien, Yang-Cheng Lee, Chung-Yi Li, Yen-Ling Lee, and Bae-Ling Chen. 2020. "BRCA1 and BRCA2 Gene Mutations and Lung Cancer Risk: A Meta-Analysis" Medicina 56, no. 5: 212. https://doi.org/10.3390/medicina56050212

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop